IPH Innate Pharma S.A.

0.9926USD0.9050 EUR · EPA-9.41%Mkt Cap: 110.87M USDP/E: —

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which …

Institutional holders1 on file

Key Statistics

Company
Market Cap110.87M USD
Enterprise Value103.22M USD
Revenue (TTM)10.76M USD
Gross Profit-33.09M USD
Net Income (TTM)-53.94M USD
Revenue/Share0.12 USD
Last Price0.9926 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees120
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010331421
Valuation
P/E (Trailing)—
P/E (Forward)1.00
PEG—
EV/EBITDA-2.00
EV/Revenue9.60
P/S10.31
P/B-2.09
EPS (TTM)-0.56 USD
EPS (Forward)0.99 USD
52W Range
0.95752% of range2.556
52W High2.556 USD
52W Low0.9575 USD
Profitability
Gross Margin0.00%
Oper. Margin-485.25%
EBITDA Margin0.00%
Profit Margin-1764.51%
ROE226.58%
ROA-78.41%
ROIC—
ROCE-204.93%
Growth
Revenue Growth16.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.71M USD
CapEx (TTM)2.58M USD
FCF Margin-295.30%
FCF Yield-28.65%
Net Debt10.21M USD
Net Debt/EBITDA-0.20
Net Debt/FCF—
Balance Sheet
Debt/Equity-1.04
Current Ratio0.60
Quick Ratio0.47
Book Value/Sh-0.47 USD
Cash/Share0.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.508 USD
Upside (mean)+555.6%
Target Range6.142 USD – 6.800 USD
6.142+555.6% to mean6.800
# Analysts3
Ownership
Shares Out.111.70M
Float68.87M
Insiders17.46%
Institutions11.72%
Technical
SMA 501.479 (-32.9%)
SMA 2001.600 (-38.0%)
Beta1.22
S&P 52W Chg12.00%
Avg Vol (30d)361.75K
Avg Vol (10d)606.22K
Technical Indicators
RSI (14)22.4
MACD-0.0692
MACD Signal-0.0410
MACD Hist.-0.0282
BB Upper1.602 USD
BB Middle1.362 USD
BB Lower1.122 USD
BB Width35.28%
ATR (14)0.0957 USD
Vol Ratio (20d)4.07x

About Innate Pharma (EPA: IPH)

›

Innate Pharma (EPA: IPH) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 120 employees.

The shares were at 0.9050 EUR on 19 November 2026, down 44.1% over 52 weeks. Its 52-week range is 0.8730 EUR to 2.330 EUR: the price is 61.2% below the high and 3.7% above the low.

Its market capitalisation is 101.09M EUR.

Innate Pharma reports return on equity of 226.6%, an operating margin of -485.2% and revenue up 16.5% year over year.

Its debt exceeds its cash by 9.31M EUR. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.